An Nfil3-Zeb2-Id2 pathway imposes Irf8 enhancer switching during cDC1 development.

MLA

Bagadia, Prachi, et al. “An Nfil3-Zeb2-Id2 Pathway Imposes Irf8 Enhancer Switching during CDC1 Development.” Nature Immunology, vol. 20, no. 9, Sept. 2019, pp. 1174–85. EBSCOhost, https://doi.org/10.1038/s41590-019-0449-3.

APA

Bagadia, P., Huang, X., Liu, T.-T., Durai, V., Grajales-Reyes, G. E., Nitschké, M., Modrusan, Z., Granja, J. M., Satpathy, A. T., Briseño, C. G., Gargaro, M., Iwata, A., Kim, S., Chang, H. Y., Shaw, A. S., Murphy, T. L., & Murphy, K. M. (2019). An Nfil3-Zeb2-Id2 pathway imposes Irf8 enhancer switching during cDC1 development. Nature Immunology, 20(9), 1174–1185. https://doi.org/10.1038/s41590-019-0449-3

Chicago

Bagadia, Prachi, Xiao Huang, Tian-Tian Liu, Vivek Durai, Gary E Grajales-Reyes, Maximilian Nitschké, Zora Modrusan, et al. 2019. “An Nfil3-Zeb2-Id2 Pathway Imposes Irf8 Enhancer Switching during CDC1 Development.” Nature Immunology 20 (9): 1174–85. doi:10.1038/s41590-019-0449-3.